Beneficial effects of topical anti-inflammatory drugs against sulfur mustard-induced ocular lesions in rabbits

Journal of Applied Toxicology

Volumn 20, Issue SUPPL. 1, 2000, Pages

  Amir, A ^a   Turetz, J ^a   Chapman, S ^a   Fishbeine, E ^a   Meshulam, J ^a   Sahar, R ^a   Liani, H ^a   Gilat, E ^a   Frishman, G ^a   Kadar, T ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Dexamethasone; Diclofenac; Inflammation; Ocular; Sulfur mustard

Indexed keywords

ANTIINFLAMMATORY AGENT; DERMATOLOGICAL AGENT; DEXAMETHASONE; DICLOFENAC; MUSTARD GAS; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; CORNEA; DRUG EFFECT; EYE; EYE DISEASE; INFLAMMATION; PATHOLOGY; RABBIT; VOLATILIZATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CORNEA; DERMATOLOGIC AGENTS; DEXAMETHASONE; DICLOFENAC; EYE; EYE DISEASES; INFLAMMATION; MUSTARD GAS; RABBITS; VOLATILIZATION;

EID: 18044402950     PISSN: 0260437X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1263(200012)20:1+<::aid-jat669>3.0.co;2-7     Document Type: Article

References (17)

1. Papirmeister B, Feister AJ, Robinson SI, Ford RD. Respiratory tract lesions. In Medical Defense Against Mustard Gas. CRC Press: Boca Raton, FL, 1991; 68.
2. Geeraets WJ, Abedi S, Blanke RV. Acute corneal injury by mustard gas. Southern Med. J. 1977; 70: 348-350.
3. Blodi FC. Mustard gas keratopathy. Int. Ophthalmol. Clin. 1971; 11: 1-13.
4. De Courcy TL. A case of mustard gas keratities under constant observation for a period of twenty years. Br. J. Ophthalmol. 1943; 27: 54-60.
5. Kadar T, Amir A, Fishbeine E, Chapman S, Liani H, Sahar R, Rabinowitz I, Simon GA, Frishman G, Sheivitz R, Turetz J. The potential therapy of steroids against ocular lesions induced by sulfur mustard vapor in rabbits. Med. Defense Biosci. Rev. 1996; 2: 845-852.
6. Ashkenasi M, Blumenthal I, Avni M, Belkin. Mustard gas injuries of the eyes. Harefuah, 1991; 120: 279-283.
7. Solberg Y, Alcalay M, Belkin M. Ocular injury by mustard gas. Surv. Ophthalmol. 1997; 41: 461-466.
8. Kurt EM, Broomfield CA, Kahler DW, Schafer RS, Arroyo CM. Immunologic cytokine expression in human keratinocytes after exposure to sulfur mustard (HD). Med. Defense Biosci. Rev. 1996; 2: 861-869.
9. Moroy SE, Lichter PR. Ocular ophthalmology. In Goodman and Oilman's The Pharmacological Basis of Therapeutics (9th edn), Hardman JG, Limbird LE, (eds). McGraw-Hill: New York, 1996; 1619-1646.
10. Barnes PJ, Adcock IM. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol. Sci. 1993; 14: 436-441.
11. Sher NA. The use of topical diclofenac sodium (Voltaren ophthalmic) in the treatment of postoperative pain after excimer photorefractive keratectomy. In Proc. Ophthalmic NSAID Roundtable, American Academy of Ophthalmologists 96th Annual Meeting, Solomon LD (ed.) 2nd edition, Medicöpea International Inc, Dallas, Texas, 1992; 85-91.
12. Masferrer JL, Kulkarni PS. Cyclooxygenase-2 inhibitors: a new approach to the therapy of ocular inflammation. Surv. Ophthalmol. 1997; 41: S35-S40.
13. Nassisse MP, McGahan MC, Shields MB, Echelman D, Fleisher LN. Inflammatory effects of continous wave neodinium: yttrium aluminum garnet laser cytophotocoagulation. Invest. Ophthalmol. Vis. Sci. 1992; 33: 2216-2223.
14. Kulkarni PS. Steroids in ocular therapy. In Textbook of Ocular Pharmacology, Zimmerman TJ, Kooner KS, Sharir M, Fechtner RD. (eds). Lippincott-Raven: Philadelphia, 1997; 61-74
15. Ben Ezra D, Wysenbeek YS, Cohen E. Increased intraocular pressure during treatment of chronic uveitis. Graefe's Arch. Clin. Exp. Ophthalmol. 1997; 235: 200-203.
16. Eiferman RA, Hoffman RS, Sher NA. Topical diclofenac reduces pain following photorefrative keratectomy. Arch. Ophthalmol. 1993; 111: 1022.
17. Ku EC, Lee W, Kothari HV, Kimble EF, Liauw L, Tjan J. The effects of diclofenac sodium on arachidonic acid metabolism. Semin. Arthritis Rheum. 1985; 15: 36-41.